SMYD3 and prostate cancer: Moreover, the authors provided evidence that SMYD3′s oncogenic properties in prostate cancer likely rely on its methyltransferase activity by showing that cell proliferation, apoptosis, and cell viability were not altered when sh-SMYD3 stably expressing cancer cells were transfected with enzymatically inactive SMYD3 [61].